MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Sales Of CortrophinGel$75,119K Sales Of ILUVIENAndYUTIQ$19,255K Total Sales Of RareDisease Pharmaceutical...$94,374K Sales Of EstablishedBrand Royalties And...$21,540K Sales Of EstablishedBrands$12,328K Sales Of GenericPharmaceutical Products$105,402K Sales Of Generic OtherRevenues$3,818K Total Sales Of RareDisease And Brands$128,242K Total Sales OfGenerics And Other$109,220K Net revenues$237,462K Operating income$38,888K Unrealized loss (gain) oninvestment in equity...$5,753K Total operatingexpenses, net$198,574K Contingent considerationfair value...-$182K Income before incometax expense$40,221K Interest expense, net-$3,769K Other (expense)income, net-$651K Cost of sales(excluding depreciation...$93,582K Selling, general, andadministrative$73,655K Depreciation andamortization$20,919K Research and development$10,600K Net income$29,492K Income tax expense$10,729K Net incomeavailable to common...$29,492K
Income Statement
source: myfinsight.com

ANI PHARMACEUTICALS INC (ANIP)

ANI PHARMACEUTICALS INC (ANIP)